首页> 外文OA文献 >E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts

【2h】

E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts

机译：E7080（Lenvatinib），一种多靶点酪氨酸激酶抑制剂，显示出针对结直肠癌异种移植物的抗肿瘤活性。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Wiegering Armin; Korb Doreen; Thalheimer Andreas; Kämmerer Ulrike; Allmanritter Jan; Matthes Niels; Linnebacher Michael; Schlegel Nicolas; Klein Ingo; Ergün Süleyman; Germer Christoph-Thomas; Otto Christoph;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts [J] . Armin Wiegering, Doreen Korb, Andreas Thalheimer, Neoplasia: an international journal for oncology research . 2014,第11期

机译：E7080（Lenvatinib），一种多靶点酪氨酸激酶抑制剂，显示出针对结直肠癌异种移植物的抗肿瘤活性。
2. 146 E7080, a novel multi-targeted tyrosine kinase inhibitor, exhibits anti-angiogenic activity via inhibition of KIT signalling in a small cell lung cancer xenograft model [J] . J.Matsui, Y.Yamamoto, K.Miyazaki, European Journal of Cancer Supplements . 2004,第8期

机译：146 E7080是一种新型的多靶点酪氨酸激酶抑制剂，在小细胞肺癌异种移植模型中通过抑制KIT信号表现出抗血管生成活性
3. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models [J] . Tohyama Osamu, Matsui Junji, Kodama Kotaro, Journal of Thyroid Research . 2014,第7期

机译：Lenvatinib（E7080）的抗肿瘤活性：在临床前人类甲状腺癌模型中靶向多种受体酪氨酸激酶的血管生成抑制剂。
4. Pharmacoproteomic study of the effects of different concentrations of Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, using triple SILAC [C] . Robert LJ Graham, Michael J Sweredoski, Sonja Hess American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：不同浓度孙氨虫，一种多靶向受体酪氨酸激酶抑制剂的疗效研究，使用三重硅胶
5. The multi-targeted receptor tyrosine kinase inhibitor, linifanib (ABT-869), induces apoptosis and inhibits proliferation of leukemia cells through phosphoinositide-3 kinase (PI3K)/AKT-dependent signaling pathways. [D] . Hernandez, Jenny Elizabeth. 2010

机译：多靶点受体酪氨酸激酶抑制剂利尼法尼（ABT-869）通过磷酸肌醇3激酶（PI3K）/ AKT依赖性信号传导途径诱导凋亡并抑制白血病细胞的增殖。
6. E7080 (Lenvatinib) a Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts [O] . Armin Wiegering, Doreen Korb, Andreas Thalheimer, 2014

机译：E7080（Lenvatinib）一种多靶点酪氨酸激酶抑制剂显示出针对结直肠癌异种移植物的抗肿瘤活性。
7. E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts [O] . Wiegering Armin, Korb Doreen, Thalheimer Andreas, 2014

机译：E7080（Lenvatinib），一种多靶点酪氨酸激酶抑制剂，显示出针对结直肠癌异种移植物的抗肿瘤活性。
8. Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Technology Assessment Report [R] . Terasawa, T., Dahabreh, I., Castaldi, P. J., 2010

机译：针对癌症治疗的选定药物遗传学测试的系统评价：CYp2D6用于乳腺癌中的他莫昔芬，KRas用于结肠直肠癌中的抗EGFR抗体，以及BCR-aBL1用于慢性髓性白血病中的酪氨酸激酶抑制剂。技术评估报告

E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts

著录项

引文网络

相似文献

相关主题

期刊订阅